We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| OpGen Inc | NASDAQ:OPGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.4916 | 0.482 | 0.54 | 0 | 09:00:00 |
From May 2019 to May 2024
Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for nearly $0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Veracyte and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children's Hospital-San Diego. Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine where she graduated with honors and a Ph.D. in Biochemistry from the University of California, Riverside.
“We are pleased to have Dr. Nova, a seasoned industry expert with a portfolio of high caliber successes, join the OpGen Board,” said Evan Jones, Chairman and CEO of OpGen. “Dr. Nova’s insights and experience from having built and advised successful molecular diagnostics companies will be invaluable as we continue to advance the development of our Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase to combat the rise of multidrug-resistant organisms in our hospitals and health systems.”
About OpGen OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 mfarmer@opgen.com InvestorRelations@opgen.com Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 cduong@macbiocom.com
1 Year OpGen Chart |
1 Month OpGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
